11:28 AM EST, 11/14/2025 (MT Newswires) -- Fennec Pharmaceuticals ( FENC ) third-quarter revenue of $12.5 million beat Wedbush's $10.9 million estimate, marking four consecutive quarters of sequential growth and the company's first cash-flow positive quarter.

Analyst David Nierengarten notes that Fennec's targeted commercial strategy is bearing fruit, with growth accelerating in the AYA (adolescent/young adult) segment. He expects to see continued adoption across large community and academic centers.

Preliminary results from the STS-J01 trial for pediatric patients are expected in the fourth-quarter.

"Given Pedmark's accelerating momentum under the company's refreshed commercial strategy, we would be buyers of shares at current levels," says Nierengarten.

Fennec is rated Outperform, with a US$13 price target.

Price: 11.24, Change: +0.26, Percent Change: +2.37